VBIO — Valion Bio, Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1787740 ·
Last close
$0.87
Market Cap
$2.79M
52W High
$1.40
52W Low
$0.72
ADV30
280,146
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,634,000 | -6,202,000 | 38,215,000 | 7,215,000 | 27,153,000 |
| Dec 2025 | -302,000 | — | -1,975,000 | -2,849,000 | 31,607,000 | 12,645,000 | 14,810,000 |
| Sep 2025 | 146,000 | -145,000 | -2,483,000 | -2,596,000 | 6,229,000 | 3,450,000 | 638,000 |
| Jun 2025 | 86,000 | 54,000 | -1,934,000 | -1,931,000 | 4,508,000 | 1,184,000 | 821,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,619,000
Investing CF
$-705,000
Financing CF
$18,347,000
CapEx
$-581,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-10.61
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-52,597,000
Inventory
$4,000
Receivables
$19,000
ST Investments
—
EBIT TTM
$-7,847,000
Pretax Income TTM
$-7,993,000
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -7,898,000 | -8,878,000 | 31,607,000 | 14,810,000 | — | -6,999,000 |
| Dec 2024 | 0 | -4,476,000 | -5,655,000 | 2,807,000 | 272,000 | — | -5,725,000 |
| Dec 2023 | 1,176,000 | -8,245,000 | -8,244,000 | 5,157,000 | 1,577,000 | — | -8,511,000 |
| Dec 2022 | 1,840,000 | -10,098,000 | -10,096,000 | 5,875,000 | 2,245,000 | — | -8,919,000 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ITOC | iTonic Holdings Ltd | $2.82M | $0.30 | — |
| IVF | INVO Fertility, Inc. | $2.68M | $1.66 | — |
| NUWE | Nuwellis, Inc. | $2.43M | $0.91 | — |
| VTAK | Catheter Precision, Inc. | $2.40M | $0.89 | — |
| GEGP | GOLD ENTERPRISE GROUP INC | $3.36M | $0.00 | — |
News headlines (Yahoo Finance, 1h cache)
VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME
2026-05-19 20:38 · Yahoo
Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform
2026-05-14 20:30 · Yahoo
VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
2026-05-14 20:05 · Yahoo
Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026
2026-05-11 12:01 · Yahoo
Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™
2026-05-06 12:08 · Yahoo
VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION
2026-05-05 12:00 · Yahoo
Valion Bio Appoints Melinda Lackey as General Counsel
2026-05-04 20:05 · Yahoo
VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME
2026-04-28 12:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.